Table 2

Description of the autoimmune liver disease group

Autoimmune hepatitis (AIH)n=11
Female, n (%)10 (91)
Age (years), median (range)50 (20–70s)
Peak LFTs at liver biopsy, median (range)
ALT (U/l)757 (165–3301)
AST/ALT0.7 (0.2–1.1)
Total bilirubin (µmol/l)54 (10–388)
Serological markers of AIH
Increased IgG, n (%)9 (82)
ANA >1/80, n (%)10 (91)
SMA >1/80 (%), n (%)10 (91)
Positive anti-actin antibodies, n (%)10 (91)
Patients with a history of extra-hepatic autoimmunity*6 (55)
Primary biliary cholangitis (PBC)n=3
Female, n (%)3 (100)
Age (years), median (range)46 (40–60s)
Peak LFT at liver biopsy, median (range)
Alkaline phosphatase (U/l)250 (240–330)
Gamma-GT (U/l)167 (101–339)
ALT (U/l)74 (49–80)
AST/ALT0.6 (0.6–0.8)
Total bilirubin (µmol/l)7 (5–11)
Serological markers of PBC
Anti-mitochondria antibodies, n (%)3 (100)
Anti-M2 antibodies, n (%)3 (100)
Patients with a history of extrahepatic autoimmunity†2 (66)
  • *Extrahepatic autoimmunity: Graves’ disease (2/11), autoimmune thyroiditis (1/11), DRESS syndrome (1/11), lymphocytic colitis (1/11), rheumatoid arthritis (1/11), type 1 diabetes mellitus (1/11).

  • †Extrahepatic autoimmunity: Rheumatoid arthritis (2/3).

  • AIH, autoimmune hepatitis; ALT, alanine aminotransferase; ANA, anti-nuclear antibody; AST, aspartate aminotransferase; Gamma-GT, gamma-glutamyl transferase; irAE, immune-related adverse event; LFT, liver function tests; SMA, smooth muscle antibody.